Literature DB >> 23195640

Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital.

Kyung Mok Sohn1, Kyong Ran Peck, Eun-Jeong Joo, Young Eun Ha, Cheol-In Kang, Doo Ryeon Chung, Nam Yong Lee, Jae-Hoon Song.   

Abstract

BACKGROUND: There are no available studies on the duration and risk factors of vancomycin-resistant enterococci (VRE) carriage after hospital discharge. In this study we investigated the duration of colonization with VRE and the risk factors for prolonged carriage in the outpatient clinic after discharge from the hospital.
METHODS: The study took place from January 2008 to September 2009. Patients were included if they were identified as persistent VRE carriers by follow-up rectal swab or stool cultures in the outpatient setting, after discharge from the hospital without clearance of VRE. The probability of culture positivity and clearance was analyzed from the discharge date. Cox regression was performed to determine the risk factors for prolonged carriage. VRE clearance was defined as VRE-negative rectal (or stool) cultures on at least three consecutive occasions a minimum of 1 week apart.
RESULTS: One hundred twenty-seven patients were included in this study. Follow-up cultures were conducted for a median of 8.86 weeks (range 1-90 weeks) after hospital discharge. The median duration of culture positivity of VRE was 5.57 weeks (range 0-50.14 weeks). Ninety-six out of 127 patients (75.6%) showed the first negative culture result at a median time of 4.86 weeks (range 0-66 weeks) after discharge. Among these patients, 15 were lost to follow-up after the first negative culture and eight were lost after the second negative culture. Sixty-eight patients (53.5%) were confirmed to have clearance of VRE during follow-up in the outpatient clinic. The median time to clearance after discharge was 8.86 weeks (range 2-90 weeks). In the cleared cases, the median time to the first negative VRE culture result was 4.71 weeks (range 0-66 weeks). Ninety percent of patients showed the first negative culture result at 25 weeks and VRE clearance at 30 weeks after discharge. Surgery or antibiotic use during admission (p = 0.048 and p = 0.001, respectively), dialysis (p = 0.046), and discharge to a nursing home or other health care institution (p = 0.025) were independently associated with prolonged colonization with VRE.
CONCLUSIONS: The median duration of VRE colonization was 5.57 weeks after hospital discharge. In the cases with clearance during follow-up, the median time to clearance after discharge was 8.86 weeks. Risk factors for prolonged carriage were surgery, antibiotic use during admission, dialysis, and discharge to a nursing home or other health care institution. Therefore, patients with these risk factors should be managed more carefully to prevent transmission of VRE in the outpatient clinic.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23195640     DOI: 10.1016/j.ijid.2012.09.019

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  23 in total

1.  Efficacy and safety of fecal microbiota transplantation for decolonization of intestinal multidrug-resistant microorganism carriage: beyond Clostridioides difficile infection.

Authors:  Young Kyung Yoon; Jin Woong Suh; Eun-Ji Kang; Jeong Yeon Kim
Journal:  Ann Med       Date:  2019-09-13       Impact factor: 4.709

2.  Predictive utility of swab screening for vancomycin-resistant Enterococcus in selection of empiric antibiotics for Enterococcus sterile-site infections: a retrospective cohort study.

Authors:  Ian Brasg; Marion Elligsen; Derek MacFadden; Nick Daneman
Journal:  CMAJ Open       Date:  2017-08-15

Review 3.  Resistance in Vancomycin-Resistant Enterococci.

Authors:  William R Miller; Barbara E Murray; Louis B Rice; Cesar A Arias
Journal:  Infect Dis Clin North Am       Date:  2020-12       Impact factor: 5.982

4.  Endocarditis caused by resistant enterococcus: an overview.

Authors:  Katherine Reyes; Marcus Zervos
Journal:  Curr Infect Dis Rep       Date:  2013-08       Impact factor: 3.725

5.  Vancomycin use in surrounding patients during critical illness and risk for persistent colonization with vancomycin-resistant Enterococcus.

Authors:  P Zachariah; D E Freedberg
Journal:  J Hosp Infect       Date:  2019-01-11       Impact factor: 3.926

6.  Long-term carriage of vancomycin-resistant enterococci in patients discharged from hospitals: a 12-year retrospective cohort study.

Authors:  Surendra Karki; Gillian Land; Stacey Aitchison; Jacqueline Kennon; Paul D R Johnson; Susan A Ballard; Karin Leder; Allen C Cheng
Journal:  J Clin Microbiol       Date:  2013-08-07       Impact factor: 5.948

7.  Comparative Epidemiology of Vancomycin-Resistant Enterococci Colonization in an Acute-Care Hospital and Its Affiliated Intermediate- and Long-Term Care Facilities in Singapore.

Authors:  Damon Tan; Htet Lin Htun; Jocelyn Koh; Kala Kanagasabai; Jia-Wei Lim; Pei-Yun Hon; Brenda Ang; Angela Chow
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

8.  A Dynamic Transmission Model to Evaluate the Effectiveness of Infection Control Strategies.

Authors:  Karim Khader; Alun Thomas; W Charles Huskins; Molly Leecaster; Yue Zhang; Tom Greene; Andrew Redd; Matthew H Samore
Journal:  Open Forum Infect Dis       Date:  2017-02-10       Impact factor: 3.835

9.  Variability of cutaneous and nasal population levels between patients colonized and infected by multidrug-resistant bacteria in two Brazilian intensive care units.

Authors:  Quésia Damaceno; Jacques R Nicoli; Adriana Oliveira
Journal:  SAGE Open Med       Date:  2015-01-13

10.  A decade of genomic history for healthcare-associated Enterococcus faecium in the United Kingdom and Ireland.

Authors:  Kathy E Raven; Sandra Reuter; Rosy Reynolds; Hayley J Brodrick; Julie E Russell; M Estée Török; Julian Parkhill; Sharon J Peacock
Journal:  Genome Res       Date:  2016-08-15       Impact factor: 9.043

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.